Presentation, diagnosis and treatment of acute rejection

Karen L. Hardinger, Daniel Brennan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the current transplant era, potent immunosuppressive agents have significantly lowered the incidence of acute cellular rejection in the first years after transplantation. Renal allograft biopsy has become the gold standard for diagnosing transplant rejection. Infiltration of lymphocytes is the hallmark, histological sign of cellular rejection. In contrast for acute humoral rejection, C4d deposition in peritubular capillaries of renal allografts has been demonstrated to be a sensitive and diagnostic marker. While pulse dose corticosteroids and polyclonal antibodies are effective treatments for cellular rejection, acute humoral rejection has a poorer prognosis and historically, has been very difficult to reverse and not well studied. Treatment regimens may include one or more of the following: anti-lymphocyte agents, plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab. This chapter will review the types of transplant rejection, histological presentation, and critically analyze available treatment options.

Original languageEnglish (US)
Title of host publicationAcute Rejection
Subtitle of host publicationRisk Factors, Management and Complications
PublisherNova Science Publishers, Inc.
Pages131-150
Number of pages20
ISBN (Print)9781619423466
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Graft Rejection
Allografts
Lymphocytes
Kidney
Plasmapheresis
Intravenous Immunoglobulins
Immunosuppressive Agents
Adrenal Cortex Hormones
Therapeutics
Transplantation
Transplants
Biopsy
Antibodies
Incidence
Rituximab
Bortezomib
eculizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hardinger, K. L., & Brennan, D. (2012). Presentation, diagnosis and treatment of acute rejection. In Acute Rejection: Risk Factors, Management and Complications (pp. 131-150). Nova Science Publishers, Inc..

Presentation, diagnosis and treatment of acute rejection. / Hardinger, Karen L.; Brennan, Daniel.

Acute Rejection: Risk Factors, Management and Complications. Nova Science Publishers, Inc., 2012. p. 131-150.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hardinger, KL & Brennan, D 2012, Presentation, diagnosis and treatment of acute rejection. in Acute Rejection: Risk Factors, Management and Complications. Nova Science Publishers, Inc., pp. 131-150.
Hardinger KL, Brennan D. Presentation, diagnosis and treatment of acute rejection. In Acute Rejection: Risk Factors, Management and Complications. Nova Science Publishers, Inc. 2012. p. 131-150
Hardinger, Karen L. ; Brennan, Daniel. / Presentation, diagnosis and treatment of acute rejection. Acute Rejection: Risk Factors, Management and Complications. Nova Science Publishers, Inc., 2012. pp. 131-150
@inbook{cbf0886dcad74c889116d85d89f48100,
title = "Presentation, diagnosis and treatment of acute rejection",
abstract = "In the current transplant era, potent immunosuppressive agents have significantly lowered the incidence of acute cellular rejection in the first years after transplantation. Renal allograft biopsy has become the gold standard for diagnosing transplant rejection. Infiltration of lymphocytes is the hallmark, histological sign of cellular rejection. In contrast for acute humoral rejection, C4d deposition in peritubular capillaries of renal allografts has been demonstrated to be a sensitive and diagnostic marker. While pulse dose corticosteroids and polyclonal antibodies are effective treatments for cellular rejection, acute humoral rejection has a poorer prognosis and historically, has been very difficult to reverse and not well studied. Treatment regimens may include one or more of the following: anti-lymphocyte agents, plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab. This chapter will review the types of transplant rejection, histological presentation, and critically analyze available treatment options.",
author = "Hardinger, {Karen L.} and Daniel Brennan",
year = "2012",
month = "12",
day = "1",
language = "English (US)",
isbn = "9781619423466",
pages = "131--150",
booktitle = "Acute Rejection",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Presentation, diagnosis and treatment of acute rejection

AU - Hardinger, Karen L.

AU - Brennan, Daniel

PY - 2012/12/1

Y1 - 2012/12/1

N2 - In the current transplant era, potent immunosuppressive agents have significantly lowered the incidence of acute cellular rejection in the first years after transplantation. Renal allograft biopsy has become the gold standard for diagnosing transplant rejection. Infiltration of lymphocytes is the hallmark, histological sign of cellular rejection. In contrast for acute humoral rejection, C4d deposition in peritubular capillaries of renal allografts has been demonstrated to be a sensitive and diagnostic marker. While pulse dose corticosteroids and polyclonal antibodies are effective treatments for cellular rejection, acute humoral rejection has a poorer prognosis and historically, has been very difficult to reverse and not well studied. Treatment regimens may include one or more of the following: anti-lymphocyte agents, plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab. This chapter will review the types of transplant rejection, histological presentation, and critically analyze available treatment options.

AB - In the current transplant era, potent immunosuppressive agents have significantly lowered the incidence of acute cellular rejection in the first years after transplantation. Renal allograft biopsy has become the gold standard for diagnosing transplant rejection. Infiltration of lymphocytes is the hallmark, histological sign of cellular rejection. In contrast for acute humoral rejection, C4d deposition in peritubular capillaries of renal allografts has been demonstrated to be a sensitive and diagnostic marker. While pulse dose corticosteroids and polyclonal antibodies are effective treatments for cellular rejection, acute humoral rejection has a poorer prognosis and historically, has been very difficult to reverse and not well studied. Treatment regimens may include one or more of the following: anti-lymphocyte agents, plasmapheresis, intravenous immunoglobulin, rituximab, bortezomib, and eculizumab. This chapter will review the types of transplant rejection, histological presentation, and critically analyze available treatment options.

UR - http://www.scopus.com/inward/record.url?scp=84892056517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892056517&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84892056517

SN - 9781619423466

SP - 131

EP - 150

BT - Acute Rejection

PB - Nova Science Publishers, Inc.

ER -